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Abstract
Background: Pseudomyxoma peritonei (PMP) is a rare disease with an estimated incidence of 1–2 cases per million
individuals per year. PMP is characterized by the accumulation of abundant mucinous or gelatinous fluid derived
from disseminated tumorous cells. Most of the tumorous cells are originated from rupture of appendiceal neoplasms,
but some are from the metastasis of cancer of the colon, ovary, fallopian tube, urachus, colorectum, gallbladder,
stomach, pancreas, lung and breast. Although frequent mutations in KRAS and/or GNAS genes have been reported,
precise molecular mechanism underlying PMP remains to be elucidated. It is of note that mucinous tumour is one of
the frequent histological features of colorectal cancer (CRC) in Lynch syndrome (LS), an autosomal dominantly
inherited disease caused by a germline mutation of the DNA mismatch repair (MMR) genes including human mutL
homolog 1 (MLH1), human mutS homolog 2 (MSH2), human mutS homolog 6 (MSH6), and postmeiotic segregation
increased 2 (PMS2). Therefore, typical LS-associated tumours show mismatch repair instability. Although LS patients are
most strongly predisposed to CRC, PMPs from mucinous CRC have not been reported in LS patients.
Case presentation: In this report, we report a case of PMP originating from an ovarian teratoma in a LS patient.
The patient had surgical treatment of PMP arising from an ovarian teratoma at the age of 38 years, and later
developed a transverse colon cancer at the age of 40. The patient’s family history fulfilled the Amsterdam
criteria, and genetic analysis of the peripheral leukocytes identified a germ line mutation in the MLH1 gene
(MLH1 c.1546dupC p.Q516PfsX3). Interestingly, immunohistochemical staining showed that the expression of
MLH1 was lost in the colon cancer as well as the ovarian teratoma. Consistent with the loss of MLH1 expression, both
tumours showed high microsatellite instability (MSI-H).
Conclusion: This case suggested that LS patients may develop various types of tumours including ovarian PMP, and
that mismatch repair deficiency may play a role in the development of PMP derived from, at least, a part of ovarian
teratomas.
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Background
Pseudomyxoma peritonei (PMP) is a very rare disorder,
and a nationwide study in Netherland disclosed that the
estimated incidence of PMP is 1–2 cases per million in-
dividuals per year [1]. The condition is characterized by
the accumulation of abundant mucinous or gelatinous
fluid that is produced from tumorous cells disseminated
in the abdominal cavity and pelvis [2]. Patients with
PMP usually suffer from abdominal distension, change
of body weight, abdominal or pelvic pain, and/or digest-
ive disorder by the accumulation of ascites and/or the
progression of disseminated lesion. Tumour cells of PMP
are most frequently derived from rupture of appendiceal
neoplasms, but occasionally from the tumours in other
organs including the ovary [1, 3], fallopian tube [4],
urachus [1, 5], colorectum [1, 6], gallbladder [7], stomach
[8], pancreas [1, 9], lung [10] and breast [11]. The average
onset of the disease is reportedly from 49 to 62 years old,
which is earlier than other abdominal malignancies [1, 12].
Several molecular studies have disclosed that frequent
mutations in KRAS and GNAS are involved in appendi-
ceal PMP [13–18]. However precise molecular mechan-
ism of PMP remains to be elucidated.
Regarding the treatment of PMP, cytoreductive surgery
(CRS) combined with hyperthermic intraperitoneal
chemotherapy (HIPEC) has greatly improved the prog-
nosis of patients. A recent study of 1000 appendiceal
PMPs revealed that 738 patients treated with complete
CRS and HIPEC showed 87.4% of 5-year and 70.3% of
10-year survival [19]. However, little is known about the
prognosis of PMP originated from ovarian teratoma.
Lynch syndrome (LS) or hereditary non-polyposis
colorectal cancer (HNPCC) is an autosomal dominantly
inherited syndrome accounting for 2–7% of all colorectal
cancers (CRC) [20, 21]. It is caused by a germline muta-
tion of the DNA mismatch repair genes (MMR) including
human mutL homolog 1 (MLH1), human mutS homolog 2
(MSH2), and to a lesser extent, human mutS homolog 6
(MSH6), and postmeiotic segregation increased 2 (PMS2).
LS is characterized by the susceptibilities for various LS-
associated tumours such as colorectal, endometrial, stom-
ach, small bowel, ovarian, urothelial, bladder, and biliary
tract cancers [22, 23]. Ovarian cancer is one of Lynch
syndrome-related extra-colorectal neoplasms and the life
time risks are 4–12%. The mean age at diagnosis of the
ovarian cancers is 42.5 years and approximately 30% of
the cancers is diagnosed before the age of 40 years [24].
The pathology type of Lynch syndrome-related ovarian
cancers is similar to sporadic ovarian cancers including
mostly epithelial cell-derived tumours. Even in sporadic
ovarian cancers, 3–8% of ovarian mucinous tumours
occur from mature cystic teratoma which indicates that
teratoma is a very rare form of ovarian tumours [25].
Although the frequency of mucinous colorectal cancer
and that of ovarian tumours are higher in the LS
patients compared with normal population, PMP has
never been reported in LS patients. Most patients with
Lynch syndrome are clinically identified by the revised
Amsterdam’s criteria, or the revised Bethesda’s guideline
for the test of microsatellite instability. The tumours
associated with LS patients commonly show microsatellite
instability, a hallmark of mismatch repair deficiency. In
addition to testing for microsatellite instability, immuno-
histochemical staining of responsible gene products is
often used for the screening of the deficiency.
Here, we report for the first time, a case of ovarian
PMP in a patient with Lynch syndrome, and show the
association of the ovarian tumour with mismatch repair
deficiency.
Case presentation
A 38 year-old woman presented with progressive abdom-
inal distension. Contrasted abdomino-pelvic CT revealed
that the distended abdominal cavity of the patient was filled
with low-density fluid, and showed a degree of scalloping
sign on the liver surface (Fig. 1a). A 7-cm sized multi-
Fig. 1 a Contrasted computed tomography showed distended abdominal cavity filled with low-density fluid. b A pelvic magnetic resonance
image of the right ovarian mass with high signal intensity on T2-weighted image
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locular cystic mass containing fat tissue, which was thought
to be originating from the right ovary, was identified in the
pelvis. However, the patient’s appendix and left ovary ap-
peared normal. Pelvic magnetic resonance image showed
cystic component with high signal intensity on T1- and T2-
weighted images, and fat-saturated T1-weighted images
showed a drop in the signal intensity of the right ovarian
mass (Fig. 1b). These imaging studies suggested a teratoma
of the right ovary resulting in pseudomyxoma peritonei.
Colonoscopy and gastroscopy were normal. The laboratory
test of tumour markers showed that CEA, CA19-9, and
CA125 were elevated to 15.5 ng/ml (Upper normal
limit [UNL] < 5 ng/ml), 59.8 U/ml (UNL < 37 U/ml), and
39.7 U/ml (UNL < 35 U/ml), respectively.
Importantly, the proband’s family history completely
fulfilled the Amsterdam criteria (Fig. 2a). The mother
suffered from appendiceal cancer, ascending colon
cancer, and endometrial cancer, a maternal brother died
of rectal cancer at the age of 51, and an older sister of
the patient died of sigmoid colon cancer at the age of
31, suggesting the possible diagnosis of LS. After genetic
counselling, a written informed consent was obtained
from the patient, and a genetic test was performed using
DNA from the patient’s peripheral blood. As a result, a
germ line mutation consisting of a single nucleotide du-
plication of C (c.1546dupC, p.Q516PfsX3) in codon516
was identified in the MLH1 gene (Fig. 2b). This mutation
was judged as a deleterious mutation because the duplica-
tion resulted in a frameshift mutation inducing a truncation
of the MLH1 protein.
An open laparotomy was performed, where abundant
mucinous ascites mixed with hair was found in the peri-
toneal cavity (Fig. 3a). In addition, surgical exploration
identified a ruptured left ovarian cystic mass of 16 cm
in size and a non-ruptured right ovarian cystic mass of
7.5 cm, but the appendix was normal. The patient
underwent complete cytoreductive surgery (CRS) in-
cluding total abdominal hysterectomy with bilateral
salpingo-oophorectomy, total peritonectomy, appendi-
cectomy, greater and lesser omentectomy, splenectomy,
cholecystectomy, and resection of the liver capsule. Follow-
ing the CRS, hyperthermic intraperitoneal chemotherapy
(HIPEC) was added with mitomycin C at 10 mg/m2 for 1 h.
The post-operative course was uneventful.
Both ovarian tumours were filled with copious gelatinous
fluids containing multiple hairs and yellowish sebaceous
materials (Fig. 3b). Histological examination revealed that
the right ovarian tumour was a mature cystic teratoma ac-
companied by an endometriotic cyst. It was reported that 3
to 8% of primary ovarian mucinous tumours are accom-
panied by teratoma [26–28]. The teratoma-associated
mucinous tumours were also described to show various
histological appearances such as cystadenomatous, border-
line tumour-like to adenocarcinoma, tumours with entity
of goblet cell carcinoid, and low grade adenomatous
mucinous tumours. Consistently, the left tumour was a
mixture of mucinous cystic tumour and teratomatous
lesion. Most of the tumour cells showed mild cellular
atypia but complex structural changes classifying the
tumour into an intermediate malignancy (Fig. 3c).
Additionally, a part of the tumour demonstrated stro-
mal invasion, which corresponds to moderately differ-
entiated adenocarcinoma. The teratomatous tumours
predominantly consist of ectodermal components such
as skin and its adnexa, cartilage, tracheobronchial epi-
thelium, and included mucin-producing epithelium
depicting lower intestinal tract (Fig. 3d). Immunohisto-
chemical study revealed that the left ovarian tumour
with intermediate malignancy was negative for CK7
(Fig. 3e), and diffusely positive for CK20 and CDX2
suggesting that it has a lower intestinal phenotype (Fig. 3f
and g). However, the region of moderately differentiated
Fig. 2 a The family tree of the patient. The patient (proband) is indicated by an arrow. Males and females are illustrated by squares and circles,
respectively. Unaffected and affected individuals are indicated by open and closed symbols, respectively. Persons deceased are shown by a slash
on the symbol. Histories of malignancy and the age of diagnosis are described under the symbols. CRC, colorectal cancer; PC, pancreatic cancer;
EC, endometrial cancer; GC, gastric cancer; HCC, hepatocellular carcinoma. b Sequence chromatogram containing the mutation (MLH1
c.1546dupC, p.Q516PfsX3). Codon 516 is underlined
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adenocarcinoma was positive for CK7 and CDX2, and
negative for CK20, indicating aberrant cytokeratin stain-
ing pattern due to malignant transformation. Histo-
logical examination of the peritoneum, omentum and
implants found mucinous material and a small amount
of tumour cells (pseudomyxoma). It is of note the hist-
ology of the appendix was normal. These data suggested
that the pseudomyxoma peritonei may result from mucin-
producing epithelial cells derived from ovarian teratoma.
To clarify the aetiology of the ovarian tumour, we
carried out microsatellite instability (MSI) analysis with
the Bethesda panel (D2S123, D5S346, D17S250, BAT25,
and BAT26). Interestingly, the DNA from the left ovar-
ian tumour was positive for MSI in three of the five
markers (Fig. 4a) indicating high microsatellite instability
(MSI-high). Additional immunohistochemical analysis
showed positive staining for MSH2 and negative for
MLH1 and PMS2 (Fig. 4b-d), which is in complete
agreement with the germ line mutation in MLH1. These
data suggested that the deficiency of mismatch repair
system was associated with the ovarian tumour.
After the surgery for PMP, the patient was enrolled in a
surveillance programme of PMP. In the 2-yearly colonos-
copy, a transverse colon cancer of 2.5 cm in size was identi-
fied. The patient underwent right hemicolectomy where no
recurrence of PMP was detected. Histological examination
of the tumour revealed tubular adenocarcinoma of the
colon with an UICC stage of pT2N0M0 (data not shown).
Since our case underwent complete CRS and HIPEC for
PMP and curative operation for transverse colon cancer, a
good prognosis of the patient is expected. However, if re-
current disease may appear in the patient, we may need to
Fig. 3 a A picture of the patient’s abdominal cavity. Arrow indicates a hair in the abdominal cavity. b Macroscopic appearance of the patient’s
ovary. c Borderline lesion containing epithelium with severe atypia in the teratoma. d Histology of the right teratoma containing various
differentiations such as squamous epithelium, hair follicles, sebaceous materials, and mucinous epithelium. e, f, and g Immunohistochemical
staining of the mucinous epithelium with anti-CK7 (e), anti-CK20 (f), and anti-CDX2 (g) antibodies
Fig. 4 a Microsatellite analysis of the PMP. Arrows depict aberrant peaks in tumorous tissues compared with non-tumorous tissues indicating
microsatellite instability-high. b-d Immunohistochemical staining of mismatch repair proteins using anti-MSH2 (b), anti-MLH1 (c), and anti-PMS2
(d) antibodies
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consider immune checkpoint inhibitors for the treatment,
because mismatch repair-deficient tumours are more ef-
fective to anti-programmed death 1 (PD1) monoclonal
antibodies [29].
Conclusion
So far three groups have reported six PMPs derived from
ovarian mature cystic teratoma [3, 25, 30]. In the papers,
data of immunohistochemical staining are shown for six
tumours. One of the six was partly CK7+, and diffuse
CK20+ and diffuse CDX2+ [25], the second case was
partly CK7+, and diffuse CK20+ and partly CDX2+ [25],
the third to fifth cases were all CK7- and diffuse CK20+
[3], and the sixth case was CK7+, CK20+, and CDX2+ [30].
These data may imply that both lower-gastrointestinal tract
type mucinous tumours and primary ovarian mucinous
tumours developed in the ovarian teratoma may become
the origin of PMPs. In this case, the patient’s teratoma
contained various types of epithelium, and the majority
of cystic lesion was shown to be lined with mucinous
epithelium similar to lower intestinal tract by histological
and immunological examination (CK7-/CK20+/CDX2+).
In addition, the epithelial cells showed from benign to
malignant transformation. The region of moderately differ-
entiated adenocarcinoma in the cystic teratoma with the
positive immunohistochemical staining for CK7, strongly
suggested that the PMP should have originated from the
primary ovarian mucinous epithelium in the teratoma.
This is the first report of PMP originating from an
ovarian mature teratoma in a Lynch syndrome patient.
Two reports of cystic teratoma in Lynch syndrome have
been archived in public databases. One of the two is a
case in a Taiwanese LS family [30], and the other is a
case of Muir-Torre syndrome, a subtype of Lynch syn-
drome involving a combination of sebaceous neoplasms
of the skin and internal malignancies [31]. However,
these two teratoma cases did not accompany PMP. Im-
portantly, the latter case showed loss of MSH2 expression
in the sebaceous adenoma within mature cystic ovarian
teratoma suggesting the involvement of mismatch repair
deficiency. Although the genetic changes associated with
teratogenesis have not been clarified, impaired mismatch
repair machinery might result in the genetic changes asso-
ciated with the teratomas.
In conclusion, mismatch repair defect may cause PMP
through the development of ovarian tumour, one of the
extra-colorectal tumours associated with Lynch syndrome.
Further studies will clarify the molecular mechanisms
underlying PMP originating from ovarian teratoma.
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